Fentanyl

Introduction Overview

Generic Name

fentanyl

Brand Name

Actiq
Lazanda
Fentora
Subsys

Dosage Form

injection
nasal spray
transdermal patch
sublingual tablet
sublingual spray
transmucosal lozenge (lollipop)

Drug Class

Opioids (narcotic analgesics)

Pharmacokinetics

Absorption:
Fentanyl is well absorbed through several routes — including intravenous injection, transdermal skin application, transmucosal absorption (buccal mucosa, sublingual), and nasal mucosa. Following IV administration, fentanyl exhibits rapid onset of action due to immediate systemic availability. Transdermal patches provide a slow, steady absorption through the skin into systemic circulation, maintaining prolonged plasma levels over 72 hours. Buccal and sublingual formulations allow rapid mucosal absorption, providing relatively fast onset comparable to parenteral administration. Nasal spray formulations absorb quickly through the nasal mucosa, leading to rapid peak plasma concentration suitable for breakthrough pain. Factors influencing absorption include skin temperature (increased temperature can enhance transdermal absorption), mucosal integrity, and presence of coadministered substances.

Distribution:
Fentanyl is highly lipophilic, which allows rapid penetration into the central nervous system (CNS). It has a large volume of distribution (approximately 3 to 8 L/kg) due to extensive uptake in fatty tissues. This lipophilicity contributes to both rapid CNS effects and a reservoir effect that prolongs elimination after extended use. Fentanyl is approximately 80-85% bound to plasma proteins, mainly alpha-1-acid glycoprotein, which affects free active drug levels. Its distribution half-life is brief due to rapid tissue uptake, especially in the brain, lungs, and muscles. Redistribution from CNS to fat stores underlies delayed offset of effects after prolonged therapy.

Metabolism:
Fentanyl undergoes extensive hepatic metabolism primarily through cytochrome P450 3A4 (CYP3A4)-mediated N-dealkylation resulting in inactive metabolites. The primary metabolite is norfentanyl, which lacks opioid activity. Variations in CYP3A4 activity, due to genetic factors, drug interactions, or hepatic impairment, can significantly affect fentanyl clearance and plasma concentrations. Metabolic pathways do not generate active metabolites; therefore, accumulation in organ impairment predominantly depends on parent drug kinetics rather than active metabolites. First-pass metabolism significantly reduces bioavailability for oral routes, which is why fentanyl is not used orally.

Elimination:
Excretion of fentanyl and its metabolites occurs mainly via the kidneys, with less than 10% of unchanged drug excreted unchanged in urine. The elimination half-life ranges widely based on administration route and duration: approximately 2 to 4 hours after IV administration, but can be significantly prolonged with chronic transdermal use due to depot effects in fat. The half-life can extend to 17 hours or more in fentanyl patches due to slow release from skin and fat stores. Renal or hepatic impairment may prolong elimination. The drug is also excreted in feces in small amounts. Clearance can be influenced by body fat content, liver function, and concomitant medications.

Dosage Forms

Available Dosage Forms:
- Injection: Fentanyl citrate sterile solution for intravenous, intramuscular, or subcutaneous injection.
- Transdermal patch: Various dose strengths (commonly ranging from 12 mcg/hr to 100 mcg/hr), applied topically and replaced every 72 hours.
- Nasal spray (Lazanda): Metered doses available starting at 100 micrograms per spray, titrated based on patient response.
- Sublingual tablet (Fentora): Buccal or sublingual tablets with strengths such as 100, 200, 400, 600, 800 mcg.
- Sublingual spray (Subsys): Metered doses, starting typically at 100 mcg per spray.
- Transmucosal lozenge (Actiq): Lozenge on a stick (lollipop) with dose strengths including 200, 400, 600, 800, 1200, and 1600 mcg.

Dosages for Adults and Adolescents:
- Transdermal patches are indicated for opioid-tolerant patients only, with doses titrated from initial strengths based on prior opioid exposure (e.g., morphine 60 mg orally daily or equivalent).
- Immediate release formulations (lozenges, nasal sprays, sublingual tablets/sprays) are reserved for breakthrough cancer pain in opioid-tolerant patients; dosing is individualized and carefully titrated to effect and tolerance.
- Injection doses vary according to clinical use, anesthesia requirements, and patient factors.

Specific Patient Populations:
- Pediatric use is generally limited and requires careful dosing and clinical judgment.
- Dose adjustments may be necessary in elderly, debilitated, or patients with hepatic or renal impairment to avoid accumulation and increased adverse effects.
- Pregnant women should only use fentanyl if clearly needed; risks of neonatal opioid withdrawal syndrome are significant.
- Transdermal patch absorption can be altered by fever or external heat sources, increasing systemic exposure risk.

Precise dosing regimens should always be customized by healthcare providers based on opioid tolerance, pain severity, formulation, and patient-specific risk factors.

Mechanism Of Action

Fentanyl is a potent synthetic opioid analgesic that exerts its effects primarily through agonism at the μ-opioid receptors (MOR) located within the central nervous system and peripheral tissues. Upon binding to these G-protein coupled receptors, fentanyl induces conformational changes that inhibit adenylate cyclase activity, decrease cAMP production, and reduce calcium influx at presynaptic terminals while enhancing potassium efflux postsynaptically. These cellular effects result in decreased neuronal excitability and neurotransmitter release.

The predominant activation of μ-opioid receptors by fentanyl leads to modulation of ascending nociceptive signals in the dorsal horn of the spinal cord, as well as alteration of pain perception and the emotional response to pain at supraspinal sites such as the thalamus and limbic system. By doing so, fentanyl produces profound analgesia, sedation, and euphoria. Additionally, fentanyl's high lipophilicity allows rapid penetration across the blood-brain barrier, facilitating a quick onset of analgesia.

Fentanyl’s mechanism includes depression of brainstem respiratory centers, which modulates respiratory drive and can result in respiratory depression, a dose-limiting and potentially fatal side effect. Compared with other opioids like morphine, fentanyl has a higher receptor affinity and potency, enabling effective analgesia at lower plasma concentrations.

Clinical studies have demonstrated fentanyl’s efficacy in treating moderate to severe chronic and breakthrough pain, including cancer-related pain and as an anesthetic adjunct. Its rapid onset and short duration of action in parenteral or transmucosal formulations make it suitable for procedural analgesia and management of episodic severe pain. However, its potency necessitates cautious dosing and close monitoring, especially considering risks of tolerance, dependence, and overdose. Comparative pharmacologic research continues to evaluate structure-activity relationships among fentanyl analogs, aiming to optimize therapeutic index and minimize adverse effects.

Pharmacological Actions

Potent full agonist activity at central and peripheral μ-opioid receptors producing analgesia.
Significant suppression of ascending pain pathways in the central nervous system.
Rapid onset of action due to high lipophilicity and CNS penetration.
Induces respiratory depression by acting on brainstem respiratory centers.
Produces sedation and euphoria through modulation of limbic system opioid receptors.
Depresses cough reflex via medullary centers.
Exhibits anti-diarrheal effects by decreasing gastrointestinal motility.
Modulates autonomic nervous system causing bradycardia and hypotension in some cases.
Can induce miosis (pupil constriction) through parasympathetic stimulation.
Suppresses hypothalamic-pituitary-adrenal axis affecting hormonal balance.
May cause nausea and vomiting via stimulation of the chemoreceptor trigger zone.
Has opioid-induced immunomodulatory effects altering immune response.
Leads to potential physical dependence and addiction with chronic use.
Produces analgesic tolerance over sustained administration.
Activates intracellular G-protein signaling cascades resulting in decreased neuronal excitability.

Therapeutic Or Clinical Uses

Management of moderate to severe chronic pain requiring continuous opioid analgesia.
Treatment of breakthrough cancer pain in patients already receiving and tolerant to opioid therapy.
Analgesia in surgical procedures as an adjunct to general anesthesia.
Management of post-operative pain where rapid and potent opioid effect is required.
Use in palliative care to improve quality of life in terminal illness.
Application in pain control where other opioids have proven inadequate or intolerable.
Treatment of neuropathic pain in certain refractory cases.
Use in procedural sedation in intensive care settings.
Management of acute pain when rapid analgesic effect is mandated.
As an alternative opioid for patients with renal impairment owing to minimal active metabolites.
Use in transdermal form for non-invasive long-term pain control.
Adjunct in anesthesia induction and maintenance.
Breakthrough pain relief via transmucosal dosage forms for rapid onset.
Management of cancer pain in opioid-tolerant adults and adolescents.
Treatment of pain in opioid-tolerant patients with chronic conditions requiring around-the-clock therapy.

Side Or Adverse Effects

Respiratory depression which can be life-threatening, characterized by decreased respiratory rate and effort.
Constipation due to decreased gastrointestinal motility and delayed transit.
Nausea and vomiting resulting from stimulation of the chemoreceptor trigger zone.
Drowsiness, sedation, and dizziness leading to impaired cognition and risk of falls.
Headache and fatigue commonly reported in chronic users.
Pruritus and skin reactions such as redness, rash, or irritation at patch application site.
Dry mouth and sweating alterations including increased perspiration or cold sensation.
Bradycardia and hypotension due to opioid-induced vasodilation and autonomic effects.
Confusional states, hallucinations, or delirium especially in elderly or debilitated patients.
Muscle rigidity at high doses or rapid IV administration affecting respiratory muscles.
Addiction, dependence, and potential for abuse or misuse.
Withdrawal symptoms including agitation, anxiety, and flu-like symptoms upon abrupt cessation.
Serotonin syndrome risk when combined with serotonergic agents.
Hypogonadism and infertility potential with long-term opioid exposure.
Allergic reactions ranging from mild hypersensitivity to anaphylaxis.

Precautions

Use only in opioid-tolerant patients to minimize risk of respiratory depression.
Monitor respiratory function closely during initiation and dose adjustments.
Avoid use in patients with severe asthma or other significant respiratory compromise.
Apply patches to intact, non-irritated skin; avoid exposing patches to heat sources.
Exercise caution in elderly, debilitated, or malnourished patients due to increased sensitivity.
Assess for drug interactions with CYP3A4 inhibitors or inducers prior to administration.
Avoid abrupt discontinuation to prevent withdrawal symptoms; taper doses appropriately.
Avoid alcohol consumption and CNS depressants to reduce risk of additive respiratory depression.
Use cautiously in patients with hepatic or renal impairment; dose adjustments may be necessary.
Discard unused patches properly to prevent accidental exposure, particularly to children and pets.
Do not change fentanyl formulation without medical supervision due to variable potency.
Pregnant women should be informed about risks of neonatal opioid withdrawal syndrome.
Avoid driving or operating hazardous machinery until individual response is known.
Guard against misuse, abuse, and diversion due to high addiction potential.
Regularly evaluate pain control and signs of opioid use disorder.

Warnings

Fentanyl can cause severe or fatal respiratory depression, especially in non-tolerant individuals.
Potential for addiction, abuse, and misuse leading to overdose and death.
Use during pregnancy can result in neonatal opioid withdrawal syndrome.
Fatal respiratory depression may occur when combined with alcohol or other CNS depressants.
Risk of life-threatening overdose if used without proper opioid tolerance assessment.
Heat exposure may increase transdermal absorption causing overdose.
Accidental exposure to patches can be fatal, particularly in children and pets.
Do not substitute fentanyl formulations or doses without medical guidance due to differing bioavailability.
Naloxone may require multiple or continuous dosing to reverse fentanyl overdose due to potency.
Close monitoring required in patients with head injury, brain tumors, or other neurological conditions.
Elderly and debilitated patients are at increased risk of serious adverse effects.
Warning against use in patients with bowel obstruction or paralytic ileus.
Warn patients to keep medication out of reach of others to prevent accidental ingestion.
Inform patients about risks of drowsiness and impaired cognitive function.
Advise on the importance of adhering strictly to prescribed dosing to prevent misuse.

Contraindication

Known hypersensitivity or allergy to fentanyl or any component of the formulation.
Patients with severe asthma or significant respiratory depression or compromised pulmonary function without assisted ventilation.
Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment.
Paralytic ileus or known or suspected gastrointestinal obstruction including bowel obstruction.
Use in opioid non-tolerant patients due to high risk of fatal respiratory depression.
Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such treatment.
Use in patients who have shown hypersensitivity to other opioid analgesics.
Primary treatment of pain from non-opioid responsive conditions, like mild or intermittent pain.
Significant respiratory compromise where ventilatory support is unavailable.
Severe hepatic impairment where metabolism and clearance can be dangerously compromised.
Use in patients with raised intracranial pressure or impaired consciousness without monitoring.
Use in patients with gastrointestinal obstruction or compromised motility states.
Patients with paralytic ileus.
Patients who have not been established on opioid therapy and are not opioid-tolerant.
Use of certain formulations (transdermal patch) in acute or post-operative pain requiring rapid onset analgesia.

Drug Interactions

CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, erythromycin) can increase fentanyl plasma levels and risk of toxicity.
CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease fentanyl efficacy via increased metabolism.
Other CNS depressants such as benzodiazepines, barbiturates, alcohol, sedatives increase risk for profound sedation, respiratory depression, coma, and death.
Monoamine oxidase inhibitors elevate risk of serotonin syndrome or severe opioid toxicity.
Muscle relaxants and antipsychotics may potentiate central nervous system and respiratory depression.
Serotonergic drugs (SSRIs, SNRIs, triptans) raise risk of serotonin syndrome.
Other opioids or opioid-containing cough suppressants lead to additive opioid toxicity.
Antihistamines, tricyclic antidepressants, and antiemetics can increase CNS depressive effects.
Certain antiretrovirals and antifungals interact via CYP3A4 modulation impacting fentanyl levels.
Drugs affecting gastrointestinal motility may alter absorption and effect of transmucosal formulations.
CNS depressants such as hypnotics, anxiolytics, and general anesthetics enhance fentanyl effects.
Drugs causing respiratory depression such as muscle relaxants or sedating antihistamines increase overdose risk.
Alcohol concomitant use significantly increases fatal respiratory depression risk.
Monitoring required when co-administering diuretics or cardiac medications due to hypotension risk.
Inhibitors or inducers of p-glycoprotein may alter fentanyl distribution and elimination.

Preparations Of The Drug

Fentanyl citrate injection: sterile solution for intravenous, intramuscular, or subcutaneous use.
Fentanyl transdermal system (patch): reservoir or matrix type adhesive patches delivering steady doses over 72 hours; available in various dose strengths.
Fentanyl transmucosal lozenge (Actiq): lozenge on a handle designed for buccal administration.
Fentanyl buccal tablets (Fentora): designed for placement between cheek and gum for buccal absorption.
Fentanyl sublingual spray (Subsys): metered dose spray delivered under the tongue.
Fentanyl nasal spray (Lazanda): metered dose nasal spray formulation for rapid mucosal absorption.
Inactive ingredients vary by formulation, including isopropyl myristate, polyisobutene adhesives for patches; mannitol, sodium starch glycolate, magnesium stearate in tablets; dehydrated ethanol, propylene glycol and flavoring agents in sprays.
Formulations designed to provide either rapid onset (nasal spray, lozenge, sublingual) or sustained analgesia (patch).
Packaging includes child-resistant features, clear labeling for opioid content, and disposal instructions to prevent accidental exposure.
Accompanying medication guides provide comprehensive instructions for safe use, storage, and disposal.
Availability of multiple dosage strengths allows individualized titration according to patient needs and opioid tolerance.
Combination of active and inactive ingredients optimized for stability, absorption, and patient tolerability across administration routes.